怀孕和产后的糖化白蛋白和血糖:一个试点研究
Marti D Soffer1,2, Kaitlyn E James1,3,4, Tanayott Thaweethai1,5
1Harvard Medical School, Boston, Massachusetts.
American journal of perinatology
|August 28, 2023
概括
在怀孕和产后期间,百分比的糖性白蛋白 (%GAlb) 降低,独立于体重指数. 这种标记物与血糖不相关,这表明对监测孕妇或产后患者血糖的效用有限.
科学领域:
- 生殖内分泌学 生殖内分泌学
- 临床化学 临床化学
- 代谢障碍 代谢障碍 代谢障碍
背景情况:
- 百分比的糖性白蛋白 (%GAlb) 反映了非怀孕个体的短期血糖.
- 在怀孕期间和产后期间%GAlb的纵向变化没有得到很好的描述.
- 了解%GAlb的动态对于评估孕妇和新母亲的血糖控制至关重要.
研究的目的:
- 描述整个怀孕和产后期间的%GAlb水平.
- 在这些阶段调查%GAlb和血糖标记之间的关系.
- 评估%GAlb在怀孕和产后妇女血糖监测中的有用性.
主要方法:
- 来自研究胰岛素和葡萄糖队列妊娠调节研究的50名妇女被研究.
- %GAlb是在怀孕 (13周和26周) 和产后 (11周) 期间采集的血样本中测量.
- 口服葡萄糖耐受性测试 (OGTTs) 和HbA1c被用于评估血糖.
主要成果:
- 总白蛋白在怀孕期间下降,产后增加.
- %GAlb从怀孕早期到晚期显著下降,并在产后保持稳定.
- 体重指数 (BMI) 与%GAlb在怀孕期间相反相关,但不是产后.
- 在任何时间点,在%GAlb和OGTT或HbA1c值之间没有发现显著的关联.
结论:
- %GAlb在怀孕和产后期间下降,尽管总白蛋白的变化.
- 与标准血糖标志物 (OGTT,HbA1c) 缺乏相关性表明%GAlb不太可能是孕妇或产后妇女血糖的可靠指标.
- 可能需要进一步的研究来探索%GAlb在这个人群中的其他潜在用途或局限性.
相关概念视频
Diabetes Mellitus: Type 2 and Gestational
2.5K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.5K
Pathophysiology of Diabetes
986
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
986
Hypoglycemia and Glucagon
295
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
295
Dipeptidyl Peptidase 4 Inhibitors
211
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
211
Hormones Regulating Blood Glucose
3.5K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
3.5K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
205
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
205


